Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
Transparent reporting of observational studies emulating a target trialthe TARGET statement
When youre done reading the article, the MOTS-C vs
Arthrospira platensis ( A
